- Syngene International is adding a GMP bioconjugation suite to its commercial biologics facility in Bengaluru, enabling fully integrated ADC services from discovery to GMP manufacturing.
- The OEB-5 rated suite will compress ADC development timelines by combining monoclonal antibody production and GMP bioconjugation at a single site, complementing existing payload and linker capabilities.
Syngene International, a global contract research, development and manufacturing organization (CRDMO), has announced the addition of a GMP bioconjugation suite at its Bengaluru commercial biologics facility (Unit 3). The new suite positions Syngene among a select group of CDMOs capable of offering full-service antibody-drug conjugate (ADC) development, from discovery through GMP manufacturing.
The OEB-5 rated suite will enable integrated production of monoclonal antibodies (mAbs) and GMP bioconjugation on a single site, supporting advanced conjugates and related modalities. Syngene’s collocated analytical and bioanalytical labs will ensure seamless integration across the development lifecycle. The facility is expected to be operational within the current financial year.
“By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing.”
Alex Del Priore, Head – LM CDMO at Syngene
Building on a decade of experience in ADC discovery and expertise in handling high-potency payloads, linkers, and mAbs in GMP-compliant facilities, Syngene will also provide process development, analytical characterisation, and scale-up for both early- and late-stage programs.
